Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142291 · ClinicalTrials.gov registry record · Phase 2
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by PhenoNet.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 12
- Study locations
NCT07142291: Recruiting Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by PhenoNet.
NCT07142291 is a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS) that is actively recruiting participants, run by PhenoNet. The registered enrollment target is 105 participants, below the 296-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (65% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07142291, a Phase 2 study of Amyotrophic Lateral Sclerosis (ALS), is actively recruiting participants, sponsored by PhenoNet.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
Primary Outcome
To evaluate the effects of PHENOGENE-1A (cromolyn) on functional changes in subjects with mild to moderate ALS using the ALS Functional Rating Scale-Revised (ALSFRS-R).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cromolyn Sodium (34.2 mg BID)
- DRUG Cromolyn Sodium (17.1 mg BID)
- DRUG Riluzole (100 mg)
Study Locations (12)
Other
- Thomayer University Hospital - Fakultní Thomayerova nemocnice - Prague
- Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie - Berlin
- Michalski i Partnerzy Lekarze Spółka Partnerska - Krakow
- SP ZOZ Szpital Uniwersytecki w Krakowie - Krakow
- Centrum Medyczne NeuroProtect (NeuroProtect Medical Center) - Warsaw
- City Clinic Research - Warsaw
- University Clinical Center of Serbia - Belgrade
California
- University of California San Diego - La Jolla
- Sutter Health - California Pacific Medical Center Research Institute - San Francisco
Arizona
- Honor Health Neurology - Bob Bove Neuroscience Institute - Scottsdale
Florida
- Mayo Clinic Jacksonville - Jacksonville
New York
- Lange Neurology - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What NCT07142291 shows while recruiting
NCT07142291 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 296-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07142291 lists 12 locations in 5 states (Other, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT07142291 about?
NCT07142291 is a clinical study titled "PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS". The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung fun...
What is the current status of trial NCT07142291?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2025-11-25. Estimated completion is 2028-03.
What conditions does trial NCT07142291 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT07142291?
The interventions under investigation include: Placebo (DRUG), Cromolyn Sodium (34.2 mg BID) (DRUG), Cromolyn Sodium (17.1 mg BID) (DRUG), Riluzole (100 mg) (DRUG).
Who is sponsoring clinical trial NCT07142291?
This trial is sponsored by PhenoNet, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142291 being conducted?
This trial has 12 study locations across Arizona, California, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07142291's enrollment target sits among peer trials
105 8th of 18 higher than 11 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
ACTIVE NOT RECRUITING · Phase 2
-
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
COMPLETED · Phase 2
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI